Stockholm - Delayed Quote SEK

SpectraCure AB (publ) (SPEC.ST)

Compare
2.9500 +0.3000 (+11.32%)
At close: 5:16:08 PM GMT+1
Loading Chart for SPEC.ST
DELL
  • Previous Close 2.6500
  • Open 2.6500
  • Bid 2.8550 x --
  • Ask 2.9500 x --
  • Day's Range 2.4150 - 3.3350
  • 52 Week Range 0.8290 - 5.1100
  • Volume 863,878
  • Avg. Volume 422,410
  • Market Cap (intraday) 286.538M
  • Beta (5Y Monthly) 0.71
  • PE Ratio (TTM) --
  • EPS (TTM) -0.2300
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

SpectraCure AB (publ) engages in the development of cancer treatment system. It develops Q-PRO, a laser device; and IDOSE software with interstitial photodynamic therapy system for the treatment of prostate cancer. The company was incorporated in 2003 and is based in Lund, Sweden.

www.spectracure.com

13

Full Time Employees

December 31

Fiscal Year Ends

Recent News: SPEC.ST

View More

Performance Overview: SPEC.ST

Trailing total returns as of 1/10/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

SPEC.ST
15.91%
OMX Stockholm 30 Index
1.64%

1-Year Return

SPEC.ST
23.97%
OMX Stockholm 30 Index
7.63%

3-Year Return

SPEC.ST
50.63%
OMX Stockholm 30 Index
5.11%

5-Year Return

SPEC.ST
88.33%
OMX Stockholm 30 Index
40.46%

Compare To: SPEC.ST

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: SPEC.ST

View More

Valuation Measures

Annual
As of 1/9/2025
  • Market Cap

    257.40M

  • Enterprise Value

    235.17M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    2.31

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -9.54%

  • Return on Equity (ttm)

    -16.50%

  • Revenue (ttm)

    318k

  • Net Income Avi to Common (ttm)

    -21.18M

  • Diluted EPS (ttm)

    -0.2300

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    35.87M

  • Total Debt/Equity (mrq)

    5.19%

  • Levered Free Cash Flow (ttm)

    -25.39M

Research Analysis: SPEC.ST

View More

Company Insights: SPEC.ST

Research Reports: SPEC.ST

View More

People Also Watch